BridgeBio Oncology Therapeutics Inc. (BBOT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.62 (-2.96% 1D, market cap $216.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BBOT ranks #612 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBOT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NATR (Nature's Sunshine Products Inc.) holds a C+ grade (68/100 RQD, P/E 11.1x, ROIC 28.9%, cap $216.1M) and KRRO (Korro Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $209.1M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while KROS leads on capital efficiency (85.0% ROIC).
Per BBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001869105), BridgeBio Oncology Therapeutics Inc. generated $0 in revenue, -$134.0M in net income, and -$114.5M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 24.1 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While BBOT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.00) and Max Pain ($2.75) forces dealer call-delta covering toward $15.61.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
BridgeBio Oncology Therapeutics Inc. (BBOT) dropped -2.96% to $2.62, trading at 2% of its 52-week range ($2.51 – $14.87). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.
Oppenheimer analyst Mazahir Alimohamed maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $22 to $16.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BBOT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BBOT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, BridgeBio Oncology Therapeutics Inc. (BBOT) ranks #612 by composite RQD confidence (37/100, grade D-) and #563 by equity capitalization ($216.5M). Within this direct 5-issuer industry benchmark cohort, NATR leads on earnings valuation at 11.1x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. NATR currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with BBOT at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BBOT
ACTIVE
BridgeBio Oncology Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -2.96% | $216.5M | Benchmark Subject |
| NATR Nature's Sunshine Products Inc. | C+ | 68/100 | 11.1x | 72.4% | 28.9% | -0.24% | $216.1M | /natr-vs-bbot → |
| KRRO Korro Bio Inc. | D | 44/100 | — | — | -35.0% | +0.81% | $209.1M | /krro-vs-bbot → |
| SLGL Sol-Gel Technologies Ltd. | D+ | 54/100 | — | — | -35.0% | -0.45% | $224.8M | /slgl-vs-bbot → |
| KROS Keros Therapeutics Inc. | C+ | 66/100 | — | — | 85.0% | -2.82% | $225.2M | /kros-vs-bbot → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), BridgeBio Oncology Therapeutics Inc. (BBOT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$134.0M, operating cash flow of -$113.9M, and free cash flow of -$114.5M (-107.9% YoY). On the balance sheet, BBOT closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$134.0M | -$113.9M | -$114.5M | $448.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$74.3M | -$55.0M | -$55.1M | $164.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$41.7K | — | — | — | — |
As of 2026-11-02, BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.62 (-2.96% 1D, market cap $216.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BBOT ranks #612 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBOT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NATR (Nature's Sunshine Products Inc.) holds a C+ grade (68/100 RQD, P/E 11.1x, ROIC 28.9%, cap $216.1M) and KRRO (Korro Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $209.1M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while KROS leads on capital efficiency (85.0% ROIC).
Per BBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001869105), BridgeBio Oncology Therapeutics Inc. generated $0 in revenue, -$134.0M in net income, and -$114.5M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BBOT last traded at $2.62 (-2.96% on volume of 314,789 shares), positioning the stock -47.60% below its 50-day simple moving average ($5.00) and -67.77% below its 200-day simple moving average ($8.13). Across its 52-week range of $2.51 to $14.87, BBOT sits at the 0.9% percentile with a 14-day RSI of 24.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.29 to $2.95).
Why BBOT Stock dropped -2.96% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, BBOT scores 37 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Taken together, the low scores on cash generation and insider conviction are the main weights against the stock. Upside drivers, as framed in the source data, would need to come from improved cash-flow generation, which the current financials do not show. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data. A prospective investor would be weighing a company with negative returns and no current free-cash-flow yield against a cash balance and moderate forensic scores.
BridgeBio Oncology Therapeutics Inc. (BBOT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.2B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M for each period shown in the SEC financials.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-145.8M | $-134.0M | N/A | $-114.5M | $373.7M | N/A |
| FY 2024 | $0.0M | $-80.9M | $-74.3M | N/A | $-55.1M | $30.9M | N/A |
| FY 2023 | $0.0M | $-0.0M | $-0.0M | N/A | N/A | N/A | N/A |
Per the SEC financials, the company reported operating losses in FY 2025 and FY 2024, with net losses of $-134.0M and $-74.3M respectively. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Reported cash rose from $30.9M to $373.7M between FY 2024 and FY 2025, and debt is listed as N/A in both periods; Debt/Equity is 0.5 per the RQD rating.
Per the recent news section, the following items were reported:
Per the butterfly supply-chain graph, no supply-chain relationship is recorded (supply_chain: NONE), and no butterfly links or proprietary signals are provided. Risk watch items drawn from the data include the 52-week range of $2.51 to $14.87 against the current price of 2.62, and the -2.96% change on the day.
Per the Butterfly Supply-Chain Graph, supply_chain is NONE and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data. The sector is listed as Health Care and the industry as Biotechnology: Pharmaceutical Preparations. Beyond these classifications, the sources provide no specific dependency mapping. A prospective investor should treat any ripple analysis for this company as unavailable in source data.
Per the analyst data section, the input is NONE, so consensus ratings and price targets from that section are not available in source data. Per the news section, MarketBeat reports a consensus rating of "Moderate Buy," Oppenheimer's price target is $16 with an Outperform rating, and Piper Sandler is reported as a Buy.
Per the holders section, the input is NONE. SEC Form 4 insider transactions, 13F institutional holdings, and Congressional trades cannot be itemized from the source data. The RQD rating references institutional accumulation and insider cluster flow, but the underlying holder records are not provided.
Real-time company headlines, analyst actions, and sector developments for BridgeBio Oncology Therapeutics Inc. (BBOT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
GlobeNewswire report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.
Welcome to the BBOT (BridgeBio Oncology Therapeutics Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on BBOT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless BridgeBio Oncology Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on BBOT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.62 (52-wk range $2.51 - $14.87), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).